Abstract:BACKGROUND AND OBJECTIVES: Myasthenia gravis (MG) is a rare neuromuscular disorder where IgG antibodies damage the communication between nerves and muscles, leading to muscle weakness that can be severe and have a significant impact on patients' lives. MG exacerbations include myasthenic crisis with respiratory failure, the most serious manifestation of MG. Recent studies have found MG prevalence increasing, especially in older patients. This study examined trends in hospital admissions and in-hospital mortality for adult patients with MG and readmissions and postdischarge mortality in older (65 years or older) adults with MG.METHODS: Data from the Nationwide Inpatient Sample (NIS), an all-payer national database of hospital discharges, were used to characterize trends in hospitalizations and in-hospital mortality related to MG exacerbations and MG crisis among adult patients aged 18 years or older. The Medicare Limited Data Set, a deidentified, longitudinal research database with demographic, enrollment, and claims data was used to assess hospitalizations, length of stay (LOS), readmissions, and 30-day postdischarge mortality among fee-for-service Medicare beneficiaries aged 65 years or older. The study period was 2010-2019. Multinomial logit models and Poisson regression were used to test for significance of trends.RESULTS: Hospitalization rates for 19,715 unique adult patients and 56,822 admissions increased from 2010 to 2019 at an average annualized rate of 4.9% (MG noncrisis: 4.4%; MG crisis: 6.8%; all <i>p</i> < 0.001). Readmission rates were approximately 20% in each study year for both crisis and noncrisis hospitalizations; the in-hospital mortality rate averaged 1.8%. Among patients aged 65 years or older, annualized increases in hospitalizations were estimated at 5.2%, 4.2%, and 7.7% for all, noncrisis, and crisis hospitalizations, respectively (all <i>p</i> < 0.001). The average LOS was stable over the study period, ranging from 11.3 to 13.1 days, but was consistently longer for MG crisis admissions. Mortality among patients aged 65 years or older was higher compared with that in all patients, averaging 5.0% across each of the study years.DISCUSSION: Increasing hospitalization rates suggest a growing burden associated with MG, especially among older adults. While readmission and mortality rates have remained stable, the increasing hospitalization rates indicate that the raw numbers of readmissions-and deaths-are also increasing. Mortality rates are considerably higher in older patients hospitalized with MG.

Pregnancy in myasthenia gravis: a retrospective analysis of maternal and neonatal outcome from a large tertiary care centre in Germany

Myasthenia Gravis and Pregnancy: Toronto Specialty Center Experience

The management of myasthenia gravis in pregnancy

Risk Factors for Pregnancy-Related Clinical Outcome in Myasthenia Gravis: a Systemic Review and Meta-Analysis

Myathenia Gravis and Pregnancy

Effect of Pregnancy and Birth on the Course of Myasthenia Gravis Before or after Transsternal Radical Thymectomy

The burden of myasthenia gravis – highlighting the impact on family planning and the role of social support

Reply to the Letter to the Editor Reply to Tellez-Zenteno

Myasthenia gravis treatment in the elderly presents with a significant iatrogenic risk: a multicentric retrospective study

Diagnosis and management of myasthenia gravis during pregnancy

Severe Recurrent Necrotizing Myopathy in Pregnancy: A Case Report.

Hospitalizations and Mortality From Myasthenia Gravis

A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England

Long-term Healthcare Resource Utilization and Costs among Patients with Myasthenia Gravis: A Swedish Nationwide Population-based Study

Burden of disease in myasthenia gravis: taking the patient’s perspective

Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients

Advances in Understanding and Managing Myasthenia Gravis: Current Trends and Future Directions

Intensive care due to myasthenia gravis: Risk factors and prognosis

Perinatal outcome in anti-NMDAr encephalitis during pregnancy—a systematic review with individual patients’ data analysis

Targeted Treatments for Myasthenia Gravis in Children and Adolescents

Persistent symptoms, exacerbations and drug side effects despite treatment in myasthenia gravis